Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001415889-25-001366
Filing Date
2025-01-13
Accepted
2025-01-13 16:15:09
Documents
1
Period of Report
2025-01-09

Document Format Files

Seq Description Document Type Size
1 form4-01132025_040101.html 4  
1 form4-01132025_040101.xml 4 4043
  Complete submission text file 0001415889-25-001366.txt   5529
Mailing Address 4000 SHORELINE COURT, SUITE 300 SOUTH SAN FRANCISCO CA 94080
Business Address 4000 SHORELINE COURT, SUITE 300 SOUTH SAN FRANCISCO CA 94080 650-822-5600
Kezar Life Sciences, Inc. (Issuer) CIK: 0001645666 (see all company filings)

EIN.: 473366145 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address C/O KEZAR LIFE SCIENCES, INC. 4000 SHORELINE COURT, SUITE 300 SOUTH SAN FRANCISCO CA 94080
Business Address
Kirk Christopher J. (Reporting) CIK: 0001744253 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-38542 | Film No.: 25526525